Oral cyclosporin plus topical corticosteroid therapy diminishes bone mass in children with eczema.
Topical corticosteroids remain the most common treatment for eczema; however, it is uncertain whether long-term use of these agents has any adverse effect on bone mass. Cyclosporin is very useful in patients with severe atopic dermatitis who have failed conventional therapy. It has been shown to induce bone loss. We compared 43 children with severe eczema who were using topical corticosteroids with 73 healthy children. Of the 43 patients, six were also taking cyclosporin. Bone mineral density was measured in the lumbar spine and in the femoral neck using dual-energy X-ray absorptiometry. In multivariate analysis, subjects with eczema had lower lumbar spine bone mineral density (-0.03 g/cm(2); p = 0.015) and bone mineral apparent density (-0.01 g/cm(3); p = 0.008) but higher FN BMAD (+0.02 g/cm(3); p = 0.029) compared with controls. Patients with eczema on topical corticosteroids who had used cyclosporin had lower lumbar spine bone mineral apparent density (-0.01; p = 0.006) compared with those only on topical corticosteroids in both adjusted and unadjusted analysis. In conclusion, children with severe eczema have decreased lumbar spine bone mass, which is primarily mediated by cyclosporin use rather than by topical corticosteroid use. This effect is likely to lead to a modest increase in the risk of wrist and forearm fractures in children using this agent.
Pedreira
Clarissa C
CC
Department of Endocrinology and Diabetes, Royal Children's Hospital, Parkville, Victoria, Australia. clarissaccarvalho@hotmail.com
King
Emma
E
Jones
Graeme
G
Moore
Elizabeth
E
Zacharin
Margaret
M
Varigos
George
G
Cameron
Fergus J
FJ
D015502:Absorptiometry, Photon; D000287:Administration, Topical; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D016572:Cyclosporine / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004485:Eczema / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D015999:Multivariate Analysis; D010024:Osteoporosis / Q000139:chemically induced*; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric
D015415:Biomarkers; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D016572:Cyclosporine